top of page



This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate
the efficacy and safety of 3 treatment regimens of oral GED-0301 versus placebo in subjects
with active CD . Approximately 1064 subjects will be randomized in a 1:1:1:1 ratio to
receive 1 of 3 double-blind, oral GED-0301 treatment regimens, or identically appearing placebo
daily for 52 weeks.

Do you Qualify?

​These questions require a yes answer to qualify.​

  • Are you at least 18 years of age?

  • Have you been clinically diagnosed for at least 3 months?

  • Have you failed or experienced intolerance to at least one of the following:
    aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants (eg, AZA,
    6-MP, or MTX); or TNF-α blocker (eg, infliximab, adalimumab, or certolizumab).

​These questions require a no answer to qualify.​

  • Are you currently pregnant, plan to become pregnant or breastfeeding?

  • Have you taken any biologic therapy for psoriasis treatment?

  • Currently suffering from any major illnesses that may require extended hospitalization?

If you think you may be eligible for this trial, please give us a call to schedule an appointment or click button below to email a request.

bottom of page